New research has identified a novel receptor that interacts with the angiotensin-converting enzyme 2 (ACE2) by which the SARS-CoV-2 enters host cells, and shown it can be inhibited with marketed drugs, reducing expression of ACE2 and blocking viral entry. Read More
Research led by Chalmers University of Technology and the Karolinska Institute in Sweden shows that glycosaminoglycans in the blood and urine can be used to detect 14 early-stage cancers. Read More
Metrion Biosciences Ltd. and The KCNC1 Foundation have established a collaboration to progress a hit identification research project for small-molecule modulators of the potassium ion channel Kv3.1, targeting KCNC1-related disorders. Read More
Major depressive disorder (MDD) was linked to impaired neural connectivity caused by astrocyte dysfunction, according to a study from the Southern Medical University in Guangzhou in collaboration with the University of Hong Kong. Read More
Pepgen Inc. has announced new preclinical data supporting the progression into clinical trials of PGN-EDODM1, its product candidate in development for the treatment of myotonic dystrophy type 1 (DM1). Read More
Researchers from Praxis Precision Medicines Inc. presented the discovery and preclinical evaluation of a novel voltage-gated sodium channel (Nav) blocker, PRAX-628, being developed as a potential antiepileptic drug candidate. Read More
A strong clinical association has been observed between epilepsy and the development of depression, however, it is difficult to study individual molecular and cellular mechanisms underlying these comorbidities in animal models. Researchers from Rutgers University have aimed to develop a cell-type-specific monogenic mouse model of epilepsy and depression comorbidities, which could serve as a tool for identifying disease mechanisms as well as for target and drug screening. Read More
CSPC Pharmaceutical Group Ltd. has obtained clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2055, an oral small-molecule 3C-like protease (3CLpro) inhibitor against SARS-CoV-2. Read More
Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have disclosed bicyclic heteroaryl derivatives acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer, Noonan syndrome, LEOPARD syndrome, fibrosis, cardiovascular and immunological disorders. Read More
Vertex Pharmaceuticals Inc. and Entrada Therapeutics Inc. have entered into a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1). Read More
BeadTech Inc. and Sogang University have synthesized compounds using pyrrolidine as a linker reported to be useful for the treatment of eczema, psoriasis, pruritus, contact and atopic dermatitis. Read More
The archetypal UbiB protein COQ8 has human homologues COQ8A and COQ8B, both with well-established connection to human disease, with inactivating mutations in COQ8A resulting in autosomal recessive cerebellar ataxia. Researchers from the University of Wisconsin-Madison and affiliated organizations have now recently reported the discovery of small-molecule inhibitors of COQ8A. Read More
Sionna Therapeutics Inc. has received FDA clearance of its IND application for SION-638, a small molecule designed to target the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A phase I study is now dosing healthy volunteers. Read More
Opna Bio AG has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney and Alzheimer's disease. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged pyrrolopyrimidine derivatives containing a pyrazine structure acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer. Read More
Quralis Corporation’s clinical trial application (CTA) for QRL-201, a first-in-class Stathmin-2 (STMN2) precision medicine for amyotrophic lateral sclerosis (ALS), has been authorized by Health Canada. Read More
Shanghai Pharmaceuticals Holding Co. Ltd. has described quinazoline compounds acting as TNF-α and/or IL-6 and/or IL-1β production inhibitors reported to be useful for the treatment of cancer, asthma, malaria, viral infections, autoimmune diseases, cardiovascular disorders, chronic obstructive pulmonary disease (COPD) and transplant rejection. Read More
